Arcutis Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Arcutis Biotherapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ARQT
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis.
CEOTodd Franklin Watanabe
CEOTodd Franklin Watanabe
Employees342
Employees342
HeadquartersWestlake Village, California
HeadquartersWestlake Village, California
Founded2016
Founded2016
Employees342
Employees342
ARQT Key Statistics
Market cap3.08B
Market cap3.08B
Price-Earnings ratio-68.77
Price-Earnings ratio-68.77
Dividend yield—
Dividend yield—
Average volume3.48M
Average volume3.48M
High today$25.35
High today$25.35
Low today$23.77
Low today$23.77
Open price$23.89
Open price$23.89
Volume2.51M
Volume2.51M
52 Week high$27.08
52 Week high$27.08
52 Week low$8.90
52 Week low$8.90
Stock Snapshot
As of today, Arcutis Biotherapeutics(ARQT) shares are valued at $25.10. The company's market cap stands at 3.08B, with a P/E ratio of -68.77.
As of 2025-11-06, Arcutis Biotherapeutics(ARQT) stock has fluctuated between $23.77 and $25.35. The current price stands at $25.10, placing the stock +5.6% above today's low and -1.0% off the high.
The Arcutis Biotherapeutics(ARQT)'s current trading volume is 2.51M, compared to an average daily volume of 3.48M.
In the last year, Arcutis Biotherapeutics(ARQT) shares hit a 52-week high of $27.08 and a 52-week low of $8.90.
In the last year, Arcutis Biotherapeutics(ARQT) shares hit a 52-week high of $27.08 and a 52-week low of $8.90.
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own ARQT. This list is generated using Robinhood data, and it’s not a recommendation.